These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

312 related items for PubMed ID: 36240540

  • 21. Mass spectrometry for therapeutic drug monitoring of anti-tuberculosis drugs.
    Kuhlin J, Sturkenboom MGG, Ghimire S, Margineanu I, van den Elsen SHJ, Simbar N, Akkerman OW, Jongedijk EM, Koster RA, Bruchfeld J, Touw DJ, Alffenaar JC.
    Clin Mass Spectrom; 2019 Sep; 14 Pt A():34-45. PubMed ID: 34934812
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis.
    Caminero JA, Sotgiu G, Zumla A, Migliori GB.
    Lancet Infect Dis; 2010 Sep; 10(9):621-9. PubMed ID: 20797644
    [Abstract] [Full Text] [Related]

  • 28. LC-MS/MS method for simultaneous quantification of the first-line anti-tuberculosis drugs and six primary metabolites in patient plasma: Implications for therapeutic drug monitoring.
    Kivrane A, Grinberga S, Sevostjanovs E, Igumnova V, Pole I, Viksna A, Bandere D, Krams A, Cirule A, Pugovics O, Ranka R.
    J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Nov 15; 1185():122986. PubMed ID: 34688197
    [Abstract] [Full Text] [Related]

  • 29. Evaluation of the broth microdilution plate methodology for susceptibility testing of Mycobacterium tuberculosis in Peru.
    Puyén ZM, Santos-Lázaro D, Vigo AN, Coronel J, Alarcón MJ, Cotrina VV, Moore DAJ.
    BMC Infect Dis; 2022 Aug 24; 22(1):705. PubMed ID: 36002805
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee.
    J Assoc Physicians India; 2006 Mar 24; 54():219-34. PubMed ID: 16800350
    [Abstract] [Full Text] [Related]

  • 34. Applicability of the shorter 'Bangladesh regimen' in high multidrug-resistant tuberculosis settings.
    Sotgiu G, Tiberi S, Centis R, D'Ambrosio L, Fuentes Z, Zumla A, Migliori GB.
    Int J Infect Dis; 2017 Mar 24; 56():190-193. PubMed ID: 27816662
    [Abstract] [Full Text] [Related]

  • 35. A four-drug standardized short regimen for highly resistant TB in South-West Nigeria.
    Fadeyi MO, Decroo T, Ortuño-Gutiérrez N, Ahmed B, Jinadu A, El-Tayeb O, Adebola W, Kehinde A, Lynen L, Gils T.
    Int Health; 2024 Jan 02; 16(1):123-125. PubMed ID: 37026448
    [Abstract] [Full Text] [Related]

  • 36. Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea.
    Yang JS, Kim KJ, Choi H, Lee SH.
    Ann Lab Med; 2018 Nov 02; 38(6):563-568. PubMed ID: 30027700
    [Abstract] [Full Text] [Related]

  • 37. Effectiveness and safety of modified fully oral 9-month treatment regimens for rifampicin-resistant tuberculosis: a prospective cohort study.
    Korotych O, Achar J, Gurbanova E, Hovhannesyan A, Lomtadze N, Ciobanu A, Skrahina A, Dravniece G, Kuksa L, Rich M, Khachatryan N, Germanovych M, Kadyrov A, Terleieva I, Akhundova I, Adenov M, Durdyeva M, Kiria N, Parpieva N, Yatskevich N, Jumayev R, Nurov R, Diktanas S, Vilc V, Migliori GB, Yedilbayev A.
    Lancet Infect Dis; 2024 Oct 02; 24(10):1151-1161. PubMed ID: 38880112
    [Abstract] [Full Text] [Related]

  • 38. Evidence-based Definition for Extensively Drug-Resistant Tuberculosis.
    Roelens M, Battista Migliori G, Rozanova L, Estill J, Campbell JR, Cegielski JP, Tiberi S, Palmero D, Fox GJ, Guglielmetti L, Sotgiu G, Brust JCM, Bang D, Lienhardt C, Lange C, Menzies D, Keiser O, Raviglione M.
    Am J Respir Crit Care Med; 2021 Sep 15; 204(6):713-722. PubMed ID: 34107231
    [Abstract] [Full Text] [Related]

  • 39. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis.
    Centers for Disease Control and Prevention.
    MMWR Recomm Rep; 2013 Oct 25; 62(RR-09):1-12. PubMed ID: 24157696
    [Abstract] [Full Text] [Related]

  • 40. Bedaquiline Drug Resistance Emergence Assessment in Multidrug-Resistant Tuberculosis (MDR-TB): a 5-Year Prospective In Vitro Surveillance Study of Bedaquiline and Other Second-Line Drug Susceptibility Testing in MDR-TB Isolates.
    Kaniga K, Hasan R, Jou R, Vasiliauskienė E, Chuchottaworn C, Ismail N, Metchock B, Miliauskas S, Viet Nhung N, Rodrigues C, Shin S, Simsek H, Smithtikarn S, Ngoc ALT, Boonyasopun J, Kazi M, Kim S, Kamolwat P, Musteikiene G, Sacopon CA, Tahseen S, Vasiliauskaitė L, Wu MH, Vally Omar S.
    J Clin Microbiol; 2022 Jan 19; 60(1):e0291920. PubMed ID: 34705538
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.